Guardant Health 3Q 2026: Revenue $360.98M, EPS ($0.93) — 10-Q Summary
Guardant Health reported 3Q 2026 revenue of $360.98M, up 36% YoY, with net loss widening to $124.36M. Growth was driven by increased oncology and Shield test volumes, while higher costs contributed to the larger loss. Oncology revenue rose 25% to $231.3M, and Shield revenue increased 180% to $67.6M.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data that could shift analyst expectations and short‑term price action.
Market read
The report offers new quantitative insight into Guardant's growth trajectory and cost structure, influencing biotech sector sentiment.
What to watch
Cost per sample reductions and potential future pricing power could improve margins.
Background
Guardant Health filed its Q3 2026 10‑Q, reporting a 36% revenue increase but a 34% widening of net loss.
Ticker impact
Q3 2026 results show revenue up 36% YoY to $360.98M but net loss widened to $124.36M, EPS -$0.93.
likely pressure as investors price in the larger net loss
Revenue growth is strong, yet the widening loss and higher expenses suggest margin deterioration, which could weigh on the share price.
Market effects
Highlights growth and cost pressures in the liquid biopsy and cancer diagnostics sector.
Impacts US biotech investors and may influence regional biotech ETFs.
Results are relevant to global cancer diagnostics markets and could affect comparable companies worldwide.
Counterpoint
Revenue acceleration may justify a longer-term upside despite the near‑term loss.
Key entities
- companyGuardant Health, Inc.
US‑listed provider of liquid biopsy tests.
